Breakthrough Device Designation was granted to a urine-based VOC spectroscopy/ML MCED test targeting prostate, bladder, and kidney cancers, potentially broadening non-blood screening modalities.
In a controlled silicone kidney model, CVAC 2.0 outperformed a FANS sheath system for moderate-to-larger stone fragments across clearance efficiency, residual volume, and surgeon ergonomics, though ...
Melissa Kestler, DNP, FNP-BC | Authors | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results